In recent years, immunotherapies such as PD-1/PD-L1-targeted therapies and chimeric antigen receptor (CAR) T cell therapies have proven to be effective treatments in clinical oncology [50,56]; however, how USP18 coordinates PD-L1 protein levels in response to tumor microenvironmental signals in CRC remains unknown. The gene discussed is USP18; the disease is neoplasm.